Abstract:A small red plant, also known by various names such as goat foot grass, red under the leaves, red back leaves, red leaf grass, red back fruit, and stone green red, is found distributed across several provinces in China, particularly in South China, Southwest, and Southeast China, with its primary concentration in regions such as Sichuan, Yunnan, Hubei, Anhui, Guizhou, Hunan, and Zhejiang. Botanically, it belongs to the Asteraceae family, within the genus Emilia sonchifolia (L.) DC. [ 1 ] Within this genus, Emilia sonchifolia (L.) DC., there are 8 Chinese patent medicines listed in the 2020 edition of the Chinese Pharmacopoeia that contain Emilia sonchifolia as a primary constituent. These medicines include Hua Hong Tablets (granules, capsule), Cold and Flu Inflammation and Cough Capsule (tablets), Lingyuan Wanying Tea, Bai Rong Cough Syrup, Bonesetters' Oil, Injuries' Oil, Wake-up-the-Spleen-and-Nourish-Children Capsule (granules), and Shaolin Bonesetter Cream. [ 2 ] According to the Dictionary of Traditional Chinese Medicine, [ 3 ] a small red plant is classified as a herbal remedy with heat-clearing, toxin-removing, anti-inflammatory, and diuretic effects. In clinical practice, it is commonly utilized for the treatment of conditions such as enteritis, dysentery, urinary tract infections, upper respiratory tract infections, conjunctivitis, oral ulcers, and canker sores. Its chemical composition primarily comprises alkaloids, flavonoids, organic acids, and terpenes, with PAs being one of its major alkaloid components. [ 4 ] PAs are a prevalent endogenous hepatotoxic component in the Asteraceae family, known for their significant hepatotoxicity, pulmonary toxicity, genotoxicity, and carcinogenicity. The hepatotoxicity of PAs has raised substantial concerns. [ 5 ] Globally, relevant authorities and health organizations, including the World Health Organization (WHO), the European Union (EU), the United States (US), Germany, the United Kingdom (UK), and others, have implemented restrictions on the use of PAs. However, in China, only limitations on Senkirkine have been specified, while other traditional Chinese medicines and proprietary Chinese medicines containing PAs remain unrestricted. This poses a considerable challenge to clinical safety and human health. Similarly, there are no clear recommendations or risk warnings associated with the use of Yi Dian Hong and its proprietary Chinese medicines, which are frequently employed for various ailments in clinical practice. Consequently, this paper aims to analyze the toxicity and mechanisms of PAs, along with the content of PAs in Yi Dian Hong and its proprietary Chinese medicines. The objective is to elucidate the risks associated with their clinical use, providing a scientific foundation for assessing the safety of these drugs in clinical practice.

Integrative Review on the Chemical Components, Pharmacology and Toxicology of Psoralea Corylifolia L. (bu Gu Zhi)

Psoralea corylifolia L.: a comprehensive review of its botany, traditional uses, phytochemistry, pharmacology, toxicology, quality control and pharmacokinetics

Screening Antitumor Compounds Psoralen and Isopsoralen from Psoralea Corylifolia L. Seeds.

Screening of hepatotoxic compounds in Psoralea corylifolia L., a traditional Chinese herbal and dietary supplement, using high-resolution mass spectrometry and high-content imaging

4-hydroxylonchocarpin and corylifol A: The potential hepatotoxic components of Psoralea corylifolia L

Research Development on Toxicity of Psoralea corylifolia L. Related to Efficacy and Chemical Material Basis

Dual Effects of Psoraleae Fructus on the Liver: Hepatoprotection or Hepatoxicity?

Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats

A Review of the Pharmacological Properties of Psoralen

Constituents Promoting Osteogenesis from the Fruits of Psoralea Corylifolia and Their Structure-Activity Relationship Study

Anti-tumor effect and hepatotoxicity mechanisms of psoralen

Phytochemistry, pharmacology and clinical applications of the traditional Chinese herb Pseudobulbus Cremastrae seu Pleiones (Shancigu): A review

Analysis of potential risks of clinical application of Yi Dian Hong and its proprietary Chinese medicines: A review

Bakuchiol Contributes to the Hepatotoxicity of Psoralea corylifolia in Rats

Five Constituents Contributed to the Psoraleae Fructus-Induced Hepatotoxicity Via Mitochondrial Dysfunction and Apoptosis

Exploring the anti-inflammatory and immunomodulatory potential of licochalcone B against psoralidin-induced liver injury

Biological Activity and Health Promoting Effects of Psoralidin.

A Systematic Review of the Immune-Regulating and Anticancer Activities of Pseudolaric Acid B

A Review on Phytochemistry and Pharmacology of Cortex Periplocae

Yin/Yang associated differential responses to Psoralea corylifolia Linn. In rat models: an integrated metabolomics and transcriptomics study

System analysis on adverse drug reaction of Chinese patent medicine containing Polygoni Multiflori Radix